BioSpace News Archive

AzurRx BioPharma, Inc. (NASDAQ: AZRX ), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today the appointment of James Sapirstein, President and CEO, as chairman of the company’s board of directors, effective immediately. Mr. Sapirstein succeeds Mr. Edward J. Borkowski,

Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the company will present an overview of the Company and provide a business update at the following virtual investor conferences.

Reported positive interim data from Phase 3 open-label SHORELINE Study showing that more than 70% of patients successfully treated with zuranolone 30 mg needed two or fewer treatment courses over one year Progressed WATERFALL Study – now closed to enrollment – investigating zuranolone for as needed treatment of major depressive disorder with data anticipated in the first half of 2021

- Cybrexa and NCI to collaborate on clinical development of Cybrexa’s lead candidate, CBX-12, to assess the safety and efficacy in oncology patients with solid tumors -

Teleflex Incorporated, a leading global provider of medical technologies for critical care and surgery, has announced it has submitted a Biologics License Application to the U.S. Food and Drug Administration for its investigational freeze dried plasma candidate.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Frank Clyburn, executive vice president and chief commercial officer, is scheduled to participate in the Cowen 41st Annual Health Care Conference on March 3, 2021 at 1:20 p.m. EST.

Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report fourth quarter and full year 2020 financial results on Wednesday, March 24, 2021, before the U.S. financial markets open.

Kamada Ltd., a plasma-derived biopharmaceutical company, announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2020, with the U.S. Securities and Exchange Commission.

It’s never easy to live with a compromised immune system. Often those who have a weakened immune system are already struggling with other things such as cancer or a transplant that require immunosuppressive medicine.

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Tuesday, March 2, 2021 to discuss the Company’s financial results for the fiscal 2021 third quarter ended December 31, 2020,